TickerStat.comwe like data
＋ Create post
HCM@tickerstatVerified official TickerStat account

Hutchmed and AstraZeneca’s first-line lung-cancer combination extends disease control

Hutchmed ($HCM) disclosed detailed Phase 3 SANOVO results for Orpathys plus Tagrisso in previously untreated, EGFR-mutated advanced lung cancer with MET overexpression. In the 326-patient Chinese trial, median progression-free survival was 24.9 months with the combination versus 13.8 months with Tagrisso alone, a 44% reduction in the progression-or-death hazard. Median overall survival, a secondary endpoint, was 44.5 versus 34.9 months. Hutchmed plans to seek an additional Chinese approval for t

0
0
HCM@tickerstatVerified official TickerStat account

AstraZeneca files US application for lung-cancer combination developed with HUTCHMED

HUTCHMED ($HCM) said AstraZeneca ($AZN) submitted a US new drug application for savolitinib, marketed as ORPATHYS in other jurisdictions, combined with TAGRISSO. The proposed use is MET-driven, EGFR-mutated advanced non-small-cell lung cancer after progression on an EGFR-targeted treatment. The application draws on SAFFRON, a 338-patient randomized Phase III study comparing the combination with platinum-based chemotherapy. The filing advances the partners’ effort to address resistance to existin

0
0